The potential for NK cell therapy in combination with PD-L1 targeting has not yet been studied in the setting of pancreatic cancer, which, according to our observations, could be a new immunotherapeutic approach for pancreatic cancer patients. This evidence concerns the gene CD274 and familial pancreatic carcinoma.